Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00229021 | Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis | PHASE3 | COMPLETED | 741 | — | — | Dec 1, 2003 | Mar 1, 2006 | Jun 10, 2011 | - | — |
| Name | Type | Description |
|---|---|---|
| doripenum | DRUG | - |
Inclusion Criteria: * Diagnosis of complicated lower urinary tract infection or pyelonephritis Exclusion Criteria: * Women who are pregnant, nursing or of child-bearing potential and not using a medically accepted, effective method of birth control * History of moderate or severe hypersensitivity...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 2 | PHASE1 | Gepotidacin, Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine HTD formulation 2 |
| CorMedix Inc. | CRMD | 1 | PHASE2 | Meropenem-Vaborbactam, Antibiotics |
| Pfizer Inc. | PFE | 1 | — | Undisclosed |
| QIAGEN NV | QGEN | 1 | — | Undisclosed |